Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Atherogenic lipid stress induces platelet hyperactivity through CD36-mediated hyposensitivity to prostacyclin-; the role of phosphodiesterase 3A.

Berger M, Raslan Z, Aburima A, Magwenzi S, Wraith KS, SPurgeon BEJ, Hindle MS, Law R, Febbraio M, Naseem KM.

Haematologica. 2019 Jul 9. pii: haematol.2018.213348. doi: 10.3324/haematol.2018.213348. [Epub ahead of print]

2.

Alterations in Platelet Alpha-Granule Secretion and Adhesion on Collagen under Flow in Mice Lacking the Atypical Rho GTPase RhoBTB3.

Berger M, Lutz DRJ, Lutz J, Khalil JS, Aburima A, Naseem KM, Rivero F.

Cells. 2019 Feb 11;8(2). pii: E149. doi: 10.3390/cells8020149.

3.

Attenuation of oxidative stress-induced lesions in skeletal muscle in a mouse model of obesity-independent hyperlipidaemia and atherosclerosis through the inhibition of Nox2 activity.

Sfyri PP, Yuldasheva NY, Tzimou A, Giallourou N, Crispi V, Aburima A, Beltran-Alvarez P, Patel K, Mougios V, Swann JR, Kearney MT, Matsakas A.

Free Radic Biol Med. 2018 Dec;129:504-519. doi: 10.1016/j.freeradbiomed.2018.10.422. Epub 2018 Oct 17.

PMID:
30342191
4.

Platelet releasate promotes skeletal myogenesis by increasing muscle stem cell commitment to differentiation and accelerates muscle regeneration following acute injury.

Scully D, Sfyri P, Verpoorten S, Papadopoulos P, Muñoz-Turrillas MC, Mitchell R, Aburima A, Patel K, Gutiérrez L, Naseem KM, Matsakas A.

Acta Physiol (Oxf). 2019 Mar;225(3):e13207. doi: 10.1111/apha.13207. Epub 2018 Nov 14.

PMID:
30339324
5.

Platelet function following induced hypoglycaemia in type 2 diabetes.

Kahal H, Aburima A, Spurgeon B, Wraith KS, Rigby AS, Sathyapalan T, Kilpatrick ES, Naseem KM, Atkin SL.

Diabetes Metab. 2018 Nov;44(5):431-436. doi: 10.1016/j.diabet.2018.04.004. Epub 2018 May 3.

6.

Dyslipidemia-associated atherogenic oxidized lipids induce platelet hyperactivity through phospholipase Cγ2-dependent reactive oxygen species generation.

Berger M, Wraith K, Woodward C, Aburima A, Raslan Z, Hindle MS, Moellmann J, Febbraio M, Naseem KM.

Platelets. 2019;30(4):467-472. doi: 10.1080/09537104.2018.1466386. Epub 2018 May 7.

7.

Reversal of stress fibre formation by Nitric Oxide mediated RhoA inhibition leads to reduction in the height of preformed thrombi.

Atkinson L, Yusuf MZ, Aburima A, Ahmed Y, Thomas SG, Naseem KM, Calaminus SDJ.

Sci Rep. 2018 Feb 14;8(1):3032. doi: 10.1038/s41598-018-21167-6.

8.

Prostacyclin reverses platelet stress fibre formation causing platelet aggregate instability.

Yusuf MZ, Raslan Z, Atkinson L, Aburima A, Thomas SG, Naseem KM, Calaminus SDJ.

Sci Rep. 2017 Jul 17;7(1):5582. doi: 10.1038/s41598-017-05817-9.

9.

cGMP signaling inhibits platelet shape change through regulation of the RhoA-Rho Kinase-MLC phosphatase signaling pathway.

Aburima A, Walladbegi K, Wake JD, Naseem KM.

J Thromb Haemost. 2017 Aug;15(8):1668-1678. doi: 10.1111/jth.13738. Epub 2017 Jul 18.

10.

The Spatiotemporal Regulation of cAMP Signaling in Blood Platelets-Old Friends and New Players.

Raslan Z, Aburima A, Naseem KM.

Front Pharmacol. 2015 Nov 10;6:266. doi: 10.3389/fphar.2015.00266. eCollection 2015.

11.

Targeting of type I protein kinase A to lipid rafts is required for platelet inhibition by the 3',5'-cyclic adenosine monophosphate-signaling pathway.

Raslan Z, Magwenzi S, Aburima A, Taskén K, Naseem KM.

J Thromb Haemost. 2015 Sep;13(9):1721-34. doi: 10.1111/jth.13042. Epub 2015 Aug 12.

12.

The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls.

Kahal H, Aburima A, Ungvari T, Rigby AS, Coady AM, Vince RV, Ajjan RA, Kilpatrick ES, Naseem KM, Atkin SL.

BMC Endocr Disord. 2015 Apr 2;15:14. doi: 10.1186/s12902-015-0005-6.

13.

Oxidized LDL activates blood platelets through CD36/NOX2-mediated inhibition of the cGMP/protein kinase G signaling cascade.

Magwenzi S, Woodward C, Wraith KS, Aburima A, Raslan Z, Jones H, McNeil C, Wheatcroft S, Yuldasheva N, Febbriao M, Kearney M, Naseem KM.

Blood. 2015 Apr 23;125(17):2693-703. doi: 10.1182/blood-2014-05-574491. Epub 2015 Feb 20.

14.

Multiplexed phosphospecific flow cytometry enables large-scale signaling profiling and drug screening in blood platelets.

Spurgeon BE, Aburima A, Oberprieler NG, Taskén K, Naseem KM.

J Thromb Haemost. 2014 Oct;12(10):1733-43. doi: 10.1111/jth.12670. Epub 2014 Sep 18.

15.

Platelet myosin light chain phosphatase: keeping it together.

Aburima A, Naseem KM.

Biochem Soc Trans. 2014 Apr;42(2):279-83. doi: 10.1042/BST20130277. Review.

PMID:
24646231
16.

Acute hypertriglyceridemia induces platelet hyperactivity that is not attenuated by insulin in polycystic ovary syndrome.

Aye MM, Kilpatrick ES, Aburima A, Wraith KS, Magwenzi S, Spurgeon B, Rigby AS, Sandeman D, Naseem KM, Atkin SL.

J Am Heart Assoc. 2014 Feb 28;3(1):e000706. doi: 10.1161/JAHA.113.000706.

17.

cAMP signaling regulates platelet myosin light chain (MLC) phosphorylation and shape change through targeting the RhoA-Rho kinase-MLC phosphatase signaling pathway.

Aburima A, Wraith KS, Raslan Z, Law R, Magwenzi S, Naseem KM.

Blood. 2013 Nov 14;122(20):3533-45. doi: 10.1182/blood-2013-03-487850. Epub 2013 Oct 7.

18.

Oxidized low-density lipoproteins induce rapid platelet activation and shape change through tyrosine kinase and Rho kinase-signaling pathways.

Wraith KS, Magwenzi S, Aburima A, Wen Y, Leake D, Naseem KM.

Blood. 2013 Jul 25;122(4):580-9. doi: 10.1182/blood-2013-04-491688. Epub 2013 May 22.

19.

Polycystic ovary syndrome has no independent effect on vascular, inflammatory or thrombotic markers when matched for obesity.

Kahal H, Aburima A, Ungvari T, Rigby AS, Dawson AJ, Coady AM, Vince RV, Ajjan RA, Kilpatrick ES, Naseem KM, Atkin SL.

Clin Endocrinol (Oxf). 2013 Aug;79(2):252-8. doi: 10.1111/cen.12137. Epub 2013 May 11.

PMID:
23278130
20.

Thrombospondin-1 induces platelet activation through CD36-dependent inhibition of the cAMP/protein kinase A signaling cascade.

Roberts W, Magwenzi S, Aburima A, Naseem KM.

Blood. 2010 Nov 18;116(20):4297-306. doi: 10.1182/blood-2010-01-265561. Epub 2010 Jul 27.

21.

Peroxynitrite causes phosphorylation of vasodilator-stimulated phosphoprotein through a PKC dependent mechanism.

Aburima A, Riba R, Naseem KM.

Platelets. 2010;21(6):421-8. doi: 10.3109/09537104.2010.483296.

PMID:
20624010
22.

Nitric oxide inhibits von Willebrand factor-mediated platelet adhesion and spreading through regulation of integrin alpha(IIb)beta(3) and myosin light chain.

Roberts W, Michno A, Aburima A, Naseem KM.

J Thromb Haemost. 2009 Dec;7(12):2106-15. doi: 10.1111/j.1538-7836.2009.03619.x. Epub 2009 Sep 18.

23.

Globular adiponectin increases cGMP formation in blood platelets independently of nitric oxide.

Riba R, Patel B, Aburima A, Naseem KM.

J Thromb Haemost. 2008 Dec;6(12):2121-31. doi: 10.1111/j.1538-7836.2008.03179.x. Epub 2008 Oct 1.

Supplemental Content

Loading ...
Support Center